NDA 215721 · Almatica
Zolpidem Tartrate
Zolpidem Tartrate · Oral
Last checked: Nov 20, 2026Latest source record: May 9, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 9, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
142
25 Phase 3, 8 recruiting
FAERS reports
24,112
18,146 serious, 3,297 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: COMPLEX SLEEP BEHAVIORS Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of Zolpidem Tartrate Capsules. Some of these events may result in serious injuries, including death. Discontinue Zolpidem Tartrate Capsules immediately if a patient experiences a complex sleep behavior [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )]. WARNING: COMPLEX SLEEP BEHAVIORS See full prescribing information for complete boxed warning. Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of Zolpidem Tartrate Capsules. Some of these events may result in serious injuries, including death. Discontinue Zolpidem Tartrate Capsules immediately if a patient experiences a complex sleep behavior. ( 4 , 5.1 )
What it is approved for
From the label in effect Oct 9, 2025.
Zolpidem Tartrate Capsules are indicated for the short-term treatment of transient insomnia characterized by difficulties with sleep initiation in adults younger than 65 years of age [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14 )] . Zolpidem Tartrate Capsules, a gamma-aminobutyric acid (GABA) A receptor positive modulator, is indicated for the short-term treatment of transient insomnia characterized by difficulties with sleep initiation in adults younger than 65 years of age ( 1 )
Mechanism: Zolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of transient insomnia through binding to the benzodiazepine site of α1 subunit containing GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 9, 2023 Original approval · Type 3 - New Dosage Form LabelMedication GuideLetter
1 products under this application
- ZOLPIDEM TARTRATE · ZOLPIDEM TARTRATE 7.5MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Zolpidem" as an intervention, any sponsor and status, largest first.
- A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for InsomniaPivotal-lookingRecruiting
University of PennsylvaniaAcademic, hospital or other
NCT07542756 · 1,200 participants (planned) · Start May 1, 2026 · Primary completion Jan 1, 2032
Drug: Diphenhydramine, 25 mg; Diphenhydramine, 50 mg and 7 more · For: Insomnia; Insomnia Disorder; Chronic Insomnia and 1 more
Sites: Philadelphia, Pennsylvania
- Efficacy and Safety of Zolpidem-MR Administered Over a Long Term Period as Needed for Insomnia (ZOLONG)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00425243 · 1,025 participants · Start Aug 2004 · Primary completion Jan 2006
Drug: zolpidem-MR (SL800750) · For: Sleep Initiation and Maintenance Disorders
Sites: Malvern, Pennsylvania
- Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)Pivotal-lookingCompleted
Eisai Inc.Eisai
NCT02783729 · 1,006 participants · Start May 31, 2016 · Primary completion Jan 30, 2018
Drug: Lemborexant; Lemborexant and 3 more · For: Insomnia
Sites: Jasper, Alabama; Glendale, Arizona; Little Rock, Arkansas · 102 sites in all
- A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With InsomniaPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00283946 · 876 participants · Start Feb 2006 · Primary completion Nov 2007
Drug: Zolpidem MR; Zolpidem · For: Sleep Initiation and Maintenance Disorders; Sleep Disorders
Sites: Chubu Region, Japan; Chugoku Region, Japan; Hokkaido Region, Japan · 8 sites in all
- Almorexant (ACT 078573) in Adult Subjects With Chronic Primary InsomniaPivotal-lookingCompleted
Midnight Pharma, LLCIndustry
NCT00608985 · 709 participants · Start Mar 2008 · Primary completion Sep 2009
Drug: almorexant; almorexant and 2 more · For: Primary Insomnia
Sites: Adelaide, Australia; Clayton, Australia; Footscray, Australia · 91 sites in all
- An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic InsomniaPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00784875 · 643 participants · Start Oct 2008 · Primary completion Feb 2010
Drug: LY2624803; LY2624803 and 2 more · For: Primary Insomnia; Secondary Insomnia
Sites: Birmingham, Alabama; Glendale, Arizona; Mesa, Arizona · 49 sites in all
- A Double-blind, Group-comparison P-III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia PatientsPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00374777 · 450 participants · Start Aug 2006 · Primary completion May 2008
Drug: zolpidem MR; nitrazepam and 1 more · For: Sleep Initiation and Maintenance Disorders
Sites: Chubu Region, Japan; Hokkaido Region, Japan; Kansai Region, Japan · 6 sites in all
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,450
- nausea1,242
- fatigue1,169
- insomnia990
- diarrhoea938
- fall931
- headache917
- completed suicide894
- pain809
- vomiting805
- dizziness801
- drug abuse772
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 528 |
| 2005 | 572 |
| 2006 | 578 |
| 2007 | 726 |
| 2008 | 618 |
| 2009 | 604 |
| 2010 | 597 |
| 2011 | 658 |
| 2012 | 872 |
| 2013 | 602 |
| 2014 | 608 |
| 2015 | 1,045 |
| 2016 | 1,566 |
| 2017 | 1,288 |
| 2018 | 1,681 |
| 2019 | 1,470 |
| 2020 | 1,329 |
| 2021 | 1,243 |
| 2022 | 1,568 |
| 2023 | 1,543 |
| 2024 | 1,688 |
| 2025 | 1,540 |
| 2026 | 1,188 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zolpidem Tartrate* (Zolpidem Tartrate)
2024 spending
$50.1M
Beneficiaries
1,483,094
7,548,054 claims
Per beneficiary
$34
$0.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $54,198,267 |
| 2021 | $59,456,351 |
| 2022 | $61,526,022 |
| 2023 | $60,777,775 |
| 2024 | $50,113,170 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, et al. · Lancet 2022 · Network Meta-Analysis, Systematic Review
- Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
Rosenberg R, Murphy P, Zammit G, et al. · JAMA Netw Open 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
McElroy H, O'Leary B, Adena M, et al. · J Manag Care Spec Pharm 2021 · Comparative Study, Network Meta-Analysis
- Zolpidem extended-release.
Moen MD, Plosker GL · CNS Drugs 2006 · Clinical Trial, Phase III, Comparative Study
- Zolpidem for the Management of Catatonia: A Systematic Review.
Gunther M, Tran N, Jiang S · J Acad Consult Liaison Psychiatry 2025 · Systematic Review
- Efficacy and safety of each class of sleep medication for major depressive disorder with insomnia symptoms: A systematic review and meta-analysis of double-blind randomized controlled trials.
Maruki T, Takeshima M, Yoshizawa K, et al. · Psychiatry Clin Neurosci 2025 · Systematic Review, Meta-Analysis
Sponsor: Almatica
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.